Grrrr
$COSCIENS Biopharma (CSCI.US)$ COSCIENS Biopharma Says 'Although Further Analysis of the Study Results Is Required, Initial Review of the Results Indicates That the Comparator Tests May Have Led to a High False Positive Rate Which Impacted Macimorelin's Ability to Reach the Primary Efficacy Endpoint.'
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
